Actavis Recalls Cartia XT Capsules Due to Aluminum Residue on Exterior
Actavis is recalling 2,628 bottles of Cartia XT capsules because fine aluminum residue was found on the exterior of the capsule shells.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class III, which the rubric associates with scores of 1 or 2. Given the presence of a foreign substance (aluminum) on the exterior of the capsules, a score of 2 (Moderate) is appropriate as it is a low-risk contamination or labeling/packaging issue rather than a cosmetic defect only.
Plain-English summary
Actavis Laboratories, FL, Inc. is recalling 2,628 bottles of Cartia XT (diltiazem HCl extended-release capsules, USP), 300 mg, 90-count bottles. The recall is due to the presence of a foreign substance, specifically fine residue or dust identified as aluminum, on the exterior of the capsule shell.
The affected product is identified by Lot # 956000M, with an expiration date of August 2016, and UPC 3-6203760090-6. The product was distributed nationwide. The capsules are manufactured by Watson Laboratories, Inc., in Corona, CA, and are available by prescription only.
Consumers with this product should stop using it and contact their healthcare provider or pharmacist for guidance. The FDA has classified this recall as Class III, indicating that use of or exposure to the violative product is not likely to cause adverse health consequences.
The recalled product
- Product
- Cartia XT (diltiazem HCl extended-release capsules, USP), Once-A-Day Dosage, 300 mg, 90-count bottles, Rx only, Manufactured by: Watson Laboratories, Inc., Corona, CA --- NDC 62037-0600-90
- Manufacturer
- Actavis Laboratories, FL, Inc.
- Category
- Drug — Prescription Medication
- Affected units
- 2,628
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot # 956000M
- Exp. Aug 2016
- UPC 3-6203760090-6
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Actavis Laboratories, FL, Inc.
See all →- LowActavis Recalls Ramipril Capsules Due to Incorrect Expiration Date Labeling
FDA (Drugs) · 2016-11-09
- ModerateActavis Recalls Metformin Hydrochloride Extended-Release Tablets for Dissolution Failure
FDA (Drugs) · 2015-10-21
- LowActavis Recalls Desmopressin Acetate Tablets with Incorrect Imprint
FDA (Drugs) · 2015-08-12
- ModerateActavis Recalls Diclofenac Sodium and Misoprostol Tablets Due to Split Tablets
FDA (Drugs) · 2014-12-03
- ModerateActavis Recalls Diclofenac Sodium and Misoprostol Tablets Due to Splitting
FDA (Drugs) · 2014-10-08
Same hazard · foreign substance
See all →- ModerateHeritage Pharmaceuticals Recalls Clindamycin Palmitate Hydrochloride Due to Foreign Particles
FDA (Drugs) · 2026-08-19
- HighPrednisolone Acetate Ophthalmic Suspension Recalled for Foreign Substance
FDA (Drugs) · 2026-07-08
- ModerateCorlanor Ivabradine Tablets Recalled for Foreign Substance Contamination
FDA (Drugs) · 2026-07-01
- LowHydroxyzine Hydrochloride Oral Solution recalled for foreign substance
FDA (Drugs) · 2026-07-01
- ModerateCorlanor ivabradine tablets recalled for presence of foreign substance
FDA (Drugs) · 2026-07-01